- Advertise
- Contact Us
- Contribute
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
- About Us
© 2023 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
Weight Management
The Endocrinology Network® Weight Management clinical resource center is the home of all content related to weight loss and obesity management. Now a full-blown epidemic, the obesity crisis is one of the most prominent and dangerous health crises in the US. This page will provide insight and perspective related to FDA approvals, the latest studies, and guideline updates related to nutrition, obesity, and weight management.
Obesity Society, National Kidney Foundation Release Report on Managing Coexisting Obesity and Kidney Disease
October 21, 2022
Released on October 21, the special joint report from the Obesity Society and National Kidney Foundation outlines the hurdles, optimization strategies, and research needs for the management of coexisiting obesity and chronic kidney disease identified during a multispecialty, scientific workshop held in April 2021.
American Gastroenterological Association Releases Guidelines for Pharmacologic Management of Obesity
October 20, 2022
Released on October 20, the American Gastroenterological Association's guidelines for obesity management with pharmacological therapy endorses semaglutide 2.4 mg (Wegovy), phentermine-topiramate ER (Qsymia), lirgalutide 3 mg (Saxenda), and naltrexone-bupropion ER (Contrave) as first-line medical therapies in addition to diet and exercise for weight loss in people with obesity.
Endocrine Month in Review: September 2022
September 25, 2022
Our endocrinology month in review spotlights the most popular content from the past month. Our top content from September 2022 includes new guideline recommendations from the ADA/EASD, new data on semaglutide 2.4 mg and tirzepatide, a label update for finerenone, & more!
Benefits of Bariatric Surgery in Adolescents Endure Beyond a Decade, Study Shows
September 20, 2022
An analysis of nearly 15 years of follow-up data from 97 patients who underwent bariatric surgery during adolescence provides insight into the benefits of surgery on weight loss and comorbidities among those with severe obesity.
Real-World Data Backs 2.4 mg Semaglutide (Wegovy) for Weight Management in Obesity
September 19, 2022
A retrospective analysis of EMR data from Mayo Clinic referral centers provides an overview of the effects of 2.4 mg semaglutide on weight loss in populations outside of clinical trial settings.
Declining Mental Health During COVID-19 Pandemic Linked to Worsening Obesity
September 17, 2022
New research from a team at University of Texas Southwestern describes the impact of the COVID-19 pandemic on mental health and subsequent increases in body weight among people with obesity.
Understanding Insulin Sensitivity, Adiposity, and Atherosclerosis, with Gregory Weiss, MD
September 05, 2022
In his most recent column, Dr. Gregory Weiss provides perspective on recent data elucidating the links between insulin sensitivity, central adiposity, and atherosclerosis.
Gastrectomy Has More Favorable Long-Term Safety Outcomes Profile for Black, Hispanic Patients with Obesity
August 31, 2022
A new study suggests there is little difference in weight loss and diabetes outcomes for Black and Hispanic patients undergoing RYGB vs sleeve gastrectomy, but significant differences were observed for safety outcomes with sleeve gastrectomy vs RYGB.
Endocrine Month in Review: August 2022
August 27, 2022
Our endocrinology month in review spotlights the most popular content from the past month. Our top content from August 2022 includes a trial examining time-restricted eating, a pair of FDA decisions, coverage of ADCES 22, and more!
Pediatric Obesity: A Bigger Problem than We Thought
August 26, 2022
Dr. Gregory Weiss reflects on a recent literature review breaking down different subtypes of pediatric obesity.